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Ventralight ST and SorbaFix Versus Physiomesh and
Securestrap in a Porcine Model
Corey R. Deeken, PhD, Brent D. Matthews, MD
ABSTRACT
Background and Objectives: The objective of this study
was to compare mesh contracture, adhesion characteristics,
tissue ingrowth, and histologic response of Ventralight ST/
SorbaFix (C.R. Bard/Davol, Warwick, RI, USA) with Physio-
mesh/Securestrap (Ethicon, Somerville, NJ, USA) in a por-
cine model of laparoscopic ventral hernia repair.
Methods: Standard laparoscopic technique was used to
bilaterally implant meshes in 10 female Yorkshire swine.
Each animal received either two Ventralight ST meshes
(oval shaped, 10.2  15.2 cm) or two Physiomesh meshes
(oval shaped 10  15 cm), one on either side of the
midline. The meshes were fixated to the intact peritoneum
with either SorbaFix (for animals receiving Ventralight ST)
or Securestrap (for animals receiving Physiomesh). There
were 5 animals in each group, yielding 10 of each mesh-
fixation combination. Mesh contracture, adhesion charac-
teristics, tissue ingrowth, and histologic response were
evaluated after 14 days by image analysis, mechanical
testing, and histologic staining (hematoxylin-eosin, Mas-
son trichrome, picrosirius red, and von Willebrand factor).
Results: Ventralight ST/SorbaFix and Physiomesh/Securestrap
exhibited a similar percentage of mesh contracture, percentage
of adhesion coverage, adhesion tenacity, collagen deposition,
and levels of necrosis (P  .05 in all cases). However, Ventra-
light ST/SorbaFix exhibited significantly less inflammation (P
.0001), fibrosis (P  .0017), hemorrhage (P  .0001), and
angiogenesis (P  .0032) and significantly greater strength of
tissue ingrowth (P .0003) than Physiomesh/Securestrap after
the 14-day implantation period.
Conclusions: Ventralight ST/SorbaFix exhibited more fa-
vorable strength of tissue ingrowth and histologic response
and similar mesh contracture and adhesion characteristics
compared with Physiomesh/Securestrap over a short-term
14-day implantation period in a preclinical porcine model.
Key Words: Absorbable fixation, Tensile strength, Adhesions,
Ventral hernia, Tissue ingrowth, Absorbable barrier mesh.
INTRODUCTION
As laparoscopic ventral hernia repair (LVHR) has gained
popularity, there has been a substantial increase in the
number and variety of mesh materials and fixation devices
marketed specifically for this application. Mesh materials
have evolved to include permanent or absorbable barrier
layers to minimize adhesion of the abdominal viscera to
the mesh when placed intraperitoneally. These barrier
layers are composed of a variety of materials ranging from
expanded polytetrafluoroethylene (as a permanent bar-
rier) to materials such as omega-3 fatty acids, oxidized
regenerated cellulose, type I collagen, poliglecaprone-25,
or hydrogels (as absorbable barriers).1,2
Absorbable barriers represent an attractive option for
LVHR. The absorbable barrier layer is typically resorbed
over a period of 30 to 240 days (1–8 months),3–6 minimiz-
ing adhesions during the critical early postoperative pe-
riod7 and allowing adequate time for the formation of a
neoperitoneum. Because the barrier is temporary, the
amount of residual permanent foreign material at the
repair site is minimized. Examples of meshes with absorb-
able barriers include C-QUR (Atrium Medical, Hudson,
New Hampshire, USA), Parietex Composite (Covidien,
Mansfield, Massachusetts, USA), Physiomesh (Ethicon,
Somerville, New Jersey, USA), Proceed (Ethicon), Se-
pramesh IP Composite (C.R. Bard/Davol, Warwick, Rhode
Island, USA), Ventralight ST (C.R. Bard/Davol), and Ven-
trio ST (C.R. Bard/Davol).
Numerous fixation devices are also available for LVHR
applications, and again, there are permanent (ie, transfas-
cial sutures and metallic tacks/clips) and absorbable (ie,
polymer constructs and fibrin sealants) fixation options.8,9
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The greatest advantage of an absorbable fixation device is
that most of these devices are resorbed over the first
postoperative year, minimizing the amount of foreign ma-
terial at the repair site over the long-term. This may help
to prevent adhesions and chronic pain, which can be
associated with the fixation device rather than the mesh
material used for the repair.10 However, absorbable fixa-
tion devices rely on strong tissue ingrowth through the
mesh and/or supplemental transfascial sutures to provide
long-term fixation of the mesh and prevent migration.
Examples of absorbable fixation devices include Absor-
baTack (Covidien), Permasorb (C.R. Bard/Davol), Secur-
estrap (Ethicon), and SorbaFix (C.R. Bard/Davol).
The composition, expected resorption times, and effec-
tiveness of many of these meshes and fixation devices
have been reviewed in the literature,1,2,5,8,9,11–15 and an
overview is presented in Table 1. However, the available
materials are constantly changing. For instance, meshes
such as Physiomesh and Ventralight ST and fixation de-
vices such as Securestrap and SorbaFix have recently
become commercially available and do not appear in
many of the studies comparing the other meshes/fixation
devices. Consequently, this study was designed to explore
the properties of these newest absorbable barrier mesh
designs and absorbable fixation devices. The objective of
this study was to compare mesh contracture, adhesion
characteristics (area covered by adhesions and tenacity of
adhesions), strength of tissue ingrowth, and host tissue
response associated with Ventralight ST/SorbaFix com-
pared with Physiomesh/Securestrap after a 14-day im-
plantation period in a porcine model of LVHR.
MATERIALS AND METHODS
Materials
Two mesh–fixation device combinations were evaluated in
this porcine model of LVHR. The first combination consisted
of Ventralight ST fixated with SorbaFix. The second combi-
nation consisted of Physiomesh fixated with Securestrap.
Ventralight ST is composed of a permanent polypropyl-
ene (PP) fiber co-knitted with an absorbable polyglycolic
acid (PGA) fiber, producing a mesh with a PP side and a
PGA side.2,16 The PGA side of the mesh is subsequently
coated with an absorbable hydrogel layer composed of so-
dium hyaluronate (HA), carboxymethylcellulose (CMC), and
polyethylene glycol (PEG). The purpose of this absorbable
HA/CMC/PEG layer is to minimize adhesion formation be-
tween the mesh and the viscera when the mesh is placed
inside the abdomen during LVHR.5 This HA/CMC/PEG layer
is expected to be fully resorbed within approximately 1
month in vivo. For the purposes of this study, Ventralight ST
was used in conjunction with SorbaFix.
SorbaFix is composed of poly-D,L-lactide and is expected
to be fully resorbed within approximately 12 months in
vivo.17 SorbaFix devices are approximately 3.4 mm in
diameter and 6.7 mm in length with a tissue penetration
depth of approximately 5 mm.17
Physiomesh is composed of a permanent PP mesh layer
encapsulated with polydioxanone (PDO) on both sides to
facilitate the bonding of two poliglecaprone-25 (Monocryl;
Ethicon) absorbable barrier layers, one to each side of the PP
mesh.2,6 The purpose of these poliglecaprone-25 layers is to
minimize adhesion formation between the mesh and the
viscera when the mesh is placed inside the abdomen during
LVHR. These poliglecaprone-25 layers are expected to be
fully resorbed within approximately 8 months in vivo. A
purple stripe (D&C Violet No. 2) of PDO material is also
applied to one side of the mesh on top of the poligle-
caprone-25 layer for orientation purposes during laparo-
scopic implantation of the Physiomesh material. For the
purposes of this study, Physiomesh was used in conjunc-
tion with Securestrap.
Securestrap is composed of a combination of PDO and a
copolymer of lactide/glycolide and is expected to be fully
resorbed within approximately 12 months in vivo.18 Se-
curestrap devices are shaped like staples and span across
mesh fibers with two prongs (6.7 mm in length) that
provide two sites of fixation per device.18
Methods
Study compliance. The Institutional Animal Care and Use
Committee of theDaVinci Biomedical ResearchProducts facility
(South Lancaster, Massachusetts, USA), where the study was
conducted, approved the experimental protocol before the start
of the study, and standard operating procedures were followed
at all times.
Animal care and operative technique. Ten female
Yorkshire swine weighing approximately 50 to 55 kg were
acquired for the study and acclimated to the facility for 6 to
7 days. Animals were fasted for 8 hours before surgery and
were sedated with 20 mg/kg ketamine, 2 mg/kg xylazine,
and 0.04 mg/kg atropine administered by intramuscular in-
jection. After sedation, the animals were intubated and main-
tained under anesthesia with isoflurane (0.5%–4% to effect
throughout the procedure). Animals were positioned in
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dorsal recumbency, and the operative area was shaved,
cleaned with 3 alternating scrubs of povidone-iodine
and 70% isopropyl alcohol solutions, and draped in the
standard fashion for aseptic surgery. Buprenorphine
hydrochloride (0.01 mg/kg, intramuscularly), Ceftiofur
(5 mg/kg, intramuscularly), and Carprofen (2 mg/kg,
subcutaneously) were administered preoperatively for
antibiotic prophylaxsis and pain relief, respectively.
Standard laparoscopic technique was used to bilaterally
implant the meshes. Each animal received either two Ventra-
light ST meshes (oval shaped, 10.2  15.2 cm) (Figure 1A)
or two Physiomesh meshes (oval shaped, 10  15 cm)
(Figure 1D), one on either side of the midline. The
meshes were fixated to the intact peritoneum with either
SorbaFix (for animals receiving Ventralight ST) (Figure
1B) or Securestrap (for animals receiving Physiomesh)
Table 1.
Mesh Materials and Fixation Devices
Product Components Resorption Time
Mesh material
C-QUR (Atrium Medical) Polypropylene Not biodegradable
Omega-3 fatty acid gel coating 90–120 d
Parietex Composite (Covidien) Polyethylene terephthalate Not biodegradable
Type I collagen layer 30 d
Physiomesh (Ethicon) Polypropylene Not biodegradable
Polydioxanone 180 d
Poliglecaprone-25 (Monocryl) 240 d
Proceed (Ethicon) Polypropylene Not biodegradable
Polydioxanone 180 d
Oxidized regenerated cellulose 28 d
Sepramesh IP Composite (C.R. Bard/Davol) Polypropylene Not biodegradable
Polyglycolic acid 50–80 d
Sodium hyaluronate 30 d
Carboxymethylcellulose 30 d
Polyethylene glycol 30 d
Ventralight ST (C.R. Bard/Davol) Polypropylene Not biodegradable
Polyglycolic acid 50–80 d
Sodium hyaluronate 30 d
Carboxymethylcellulose 30 d
Polyethylene glycol 30 d
Ventrio ST (C.R. Bard/Davol) Polypropylene Not biodegradable
Polyglycolic acid 50–80 d
Sodium hyaluronate 30 d
Carboxymethylcellulose 30 d
Polyethylene glycol 30 d
Polydioxanone 170–220 d
Fixation device
AbsorbaTack (Covidien) Co-polymer poly-(glycolide-co-L-lactide) 365 d
Permasorb (C.R. Bard/Davol) Poly-D,L-lactide 480 d
Securestrap (Ethicon) Polydioxanone and a co-polymer of lactide/glycolide 365 d
SorbaFix (C.R. Bard/Davol) Poly-D,L-lactide 365 d
JSLS (2013)17:549–559 551
(Figure 1E). There were 5 animals in each group, yield-
ing 10 of each mesh-fixation combination. Each mesh was
fixated with 32 of the appropriate fixation constructs (16
forming an inner ring and 16 forming an outer ring), as
shown in Figures 1C and 1F.
Once the animals recovered from anesthesia, they were
returned to their pens with free access to food and water.
Buprenorphine was administered (0.01 mg/kg, intramus-
cularly) twice a day for the first postoperative day for pain
relief and then discontinued because none of the animals
exhibited signs of pain or discomfort beyond this point.
Animals were observed daily during the 14-day implanta-
tion period for abnormalities of appearance or behavior
that might indicate adverse health effects. The abdominal
region of each animal was examined to assess the condi-
tion of the wound and the subcutaneous tissues for evi-
dence of seromas and/or hematomas.
After the 14-day implantation period, each animal was sedated
and anesthetized as previously described. Laparoscopy was
performed to visually assess each mesh, and photographs
were taken to document findings (Figures 2A and 2C).
Humane euthanasia was achieved by administering an over-
dose of pentobarbital sodium (60–150 mg/kg, intravenously
to effect) according to the American Veterinary Medical As-
sociation guidelines.19 After euthanasia, the skin and adipose
tissue were removed from the abdominal wall and the entire
abdomen was dissected to expose the meshes. The entire
abdominal wall was then explanted en bloc, photographed
(Figures 2B, 2D, and 2E), and visually inspected to
assess the integrity of the repair site, peritoneal tissue
attachments (adhesions), and mesh contracture. Each
mesh was placed in saline solution (0.9% sodium chlo-
ride) and refrigerated overnight before mechanical test-
ing the following day.
Mesh Contracture and Adhesion Area
Each mesh was photographed with a ruler included for
scale. Mesh dimensions and percent area covered by
adhesions were assessed with ImageJ software (http://
rsbweb.nih.gov/ij/) as described previously.12
Figure 1. A, Ventralight ST before implantation. B, SorbaFix before implantation. C, Ventralight ST after laparoscopic implantation and
placement of SorbaFix fixation devices. D, Physiomesh before implantation. E, Securestrap before implantation. F, Physiomesh after
laparoscopic implantation and placement of Securestrap fixation devices.
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Adhesion Tenacity
Adhesion tenacity was evaluated with the following scor-
ing as described previously12: 0, no adhesions observed;
1, loose adhesion requiring blunt dissection only; 2, firm
adhesion requiring sharp dissection without extensive
vascularity; 3, firm adhesion requiring sharp dissection
with extensive vascularity; 4, firm adhesion requiring
sharp dissection with extensive fibrotic ingrowth and ex-
tensive vascularity; and 5, grade 4 with firm attachment to
visceral organs (bowel, liver, spleen).
Mechanical Testing
Mechanical testing (T-peel test) was conducted as follows.
Specimens were brought to room temperature and pre-
pared into uniform specimens measuring 2 6 cm (avoid-
ing areas containing fixation devices) by use of an arbor
press and a rectangular die. Three mesh specimens were
prepared for each Physiomesh/Securestrap to evaluate the
strength of tissue ingrowth through an area containing the
PDO marker (n  1), as well as the strength of tissue
ingrowth through areas without the PDO marker (n  2).
Only two mesh specimens were prepared for each Ven-
tralight ST/SorbaFix because this mesh is uniform across
the entire surface and does not contain a marker region.
The mesh was separated from the abdominal wall tissue at
one end of each rectangular specimen to create a sepa-
rated area measuring 1.5  2 cm. The mesh layer was
placed in one of the pneumatic grips of the Instron ser-
vohydraulic test frame (Instron, Norwood, Massachusetts,
USA) and secured with a pressure of 45 psi, and the
abdominal wall tissue was similarly secured in the other
pneumatic grip (Figures 3A and 3B). The mesh was then
peeled from the underlying abdominal wall tissue at a rate of 25
mm/min until themeshwas disrupted from the abdominal wall
tissue. The force-versus-displacement data were used to calcu-
late theT-peel force by averaging the consistent separationdata.
The T-peel force was then normalized to the width of the
specimen by dividing by 20 mm, yielding T-peel strength in
units of newtons per centimeter.
Histology
One specimen (2  2 cm) was also prepared from each
mesh for histologic assessment. Each specimen was stored
in 10% neutral buffered formalin, embedded, sectioned,
and stained with hematoxylin-eosin, Masson trichrome,
picrosirius red, and von Willebrand factor. All slides were
Figure 2. Ventralight ST/SorbaFix after 14-day implantation period: laparoscopic view (A) and macroscopic view (B). Physiomesh/
Securestrap after 14-day implantation period: laparoscopic view (C), macroscopic view (D), and inhibition of tissue integration at PDO
marker and “reactive peritoneum” on and surrounding mesh (E).
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evaluated by a board-certified veterinary pathologist, and
representative photographs were taken of each slide. Slides
were scored for inflammatory cell infiltrates (mast cells, neu-
trophils, eosinophils, lymphocytes, plasma cells, macro-
phages, and giant cells), collagen deposition (type I and type
III collagen), fibroplasia/fibrosis (granulation tissue), hemor-
rhage, necrosis, and angiogenesis by use of the following
scoring as described previously12: 0, no response; 1, mini-
mal/barely detectable; 2, mild/slightly detectable; 3, moder-
ate/easily detectable; and 4, marked/very evident.
Statistical Analysis
Systat software (version 12.0; Systat Software, Chicago, IL,
USA) was used to perform all statistical analyses. For
continuous data in which two groups of data were com-
pared (ie, percent mesh contracture and percent area
covered by adhesions), an unpaired, 2-tailed t test was
performed. For continuous data in which 3 groups of data
were compared (ie, T-peel strength), a 1-way analysis of
variance was performed followed by a Fisher Least Signif-
icant Difference post-test as appropriate. For scores such
as adhesion tenacity and histologic parameters in which
two groups of data were compared, a nonparametric test
(Mann-Whitney) was performed. Statistical significance
was set at the P  .05 level. All data are reported as
mean  standard error of the mean.
RESULTS
Macroscopic Appearance at Explantation
Localized red discoloration or redness was observed for
many of the Ventralight ST/SorbaFix specimens (Figures
2A and 2B) in the regions where the mesh was slightly
wrinkled/folded with no appreciable or pathologically
meaningful microscopic correlate. However, frequent and
widespread to diffuse red discoloration was observed for
all of the Physiomesh/Securestrap specimens (Figures
2C, 2D, and 2E). These macroscopic observations corre-
lated microscopically with varying degrees of hemorrhage
that was associated with active and ongoing granulation
tissue ingrowth, incomplete integration of the mesh, and
incomplete tissue coverage. In addition, omental adhe-
sions were observed for 3 of 10 Ventralight ST/SorbaFix
Figure 3. A, Ventralight ST/SorbaFix specimen during T-peel testing (abdominal wall tissue in upper grip and mesh in lower grip of machine). B,
Physiomesh/Securestrap specimen during T-peel testing (the central region shows the PDO marker with minimal tissue ingrowth visible).
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specimens (30%) and 5 of 10 Physiomesh/Securestrap
specimens (50%) at the time of explantation. Further-
more, serous fluid accumulation was observed between
the mesh and abdominal wall (particularly under the
PDO marker region) in 5 of 10 Physiomesh/Securestrap
meshes (50%) and in 1 of 10 Ventralight ST/SorbaFix
meshes (10%). Inflammation of the spiral colon was ob-
served in 1 of 10 Physiomesh/Securestrap specimens (10%).
Mesh Contracture
Image analysis showed that Ventralight ST/SorbaFix con-
tracted 16.9%  2.7% compared with 17.0%  2.6% for
Physiomesh/Securestrap (Table 2). Statistically, the differ-
ence was not significant (P  .9746).
Adhesion Area
Adhesions covered 1.2%  0.7% of Ventralight ST/Sorba-
Fix compared with 6.0%  3.5% of Physiomesh/Secur-
estrap (Table 2), indicating a very small area of adhesion
on each mesh. Most adhesions were observed near the
periphery of the mesh or at one of the fixation points.
Statistically, the difference was not significant (P .1896).
Adhesion Tenacity
The tenacity of adhesions covering Ventralight ST/Sorba-
Fix scored 0.4  0.2 compared with 1.1  0.4 for Phys-
iomesh/Securestrap (Table 2). Statistically, the difference
was not significant (P  .2140). Adhesion tenacity in this
range of 0.4 to 1.1 (on a scale of 0–5) indicates that the
observed adhesions were loose and filmy, requiring only
blunt dissection to free them from the surface of the mesh.
This compares well with the low percentage of mesh
covered by adhesions, as well as the narrative descriptions
at the time of explantation, which indicated that adhesions
between the omentum and the mesh were observed for
30% of Ventralight ST/SorbaFix specimens and 50% of
Physiomesh/Securestrap specimens.
Mechanical Testing
At the time of explantation, a visual difference was ob-
served between the poliglecaprone-25 regions of the
Physiomesh/Securestrap and those regions containing the
purple PDO orientation marker. It appeared that very little
tissue ingrowth occurred in the region of the PDO marker
compared with the rest of the mesh (as shown in Figures
2D, 2E, and 3B). Thus, two sets of specimens were pre-
pared for mechanical testing of the Physiomesh/Secur-
estrap group. One set of specimens was prepared in such
a way as to avoid the PDO region completely, whereas
another set was prepared that contained only this PDO
region. In this way the strength of tissue ingrowth associ-
ated with each region of the mesh could be evaluated
mechanically by the T-peel test. Because Ventralight ST/
SorbaFix is homogeneous in composition and does not
contain a PDO marker region, only one set of specimens
was prepared for this material. The results of the T-peel
test showed significantly reduced tissue ingrowth strength
in the PDO region of Physiomesh/Securestrap (0.2  0.0
N/cm, P  .0001) (Table 2) compared with the mesh
region of Physiomesh/Securestrap (0.9  0.1 N/cm). In
addition, tissue ingrowth into Ventralight ST/SorbaFix
(1.4  0.1 N/cm) was significantly greater than the Phys-
iomesh/Securestrap mesh region (P  .0003) and PDO
marker region (P  .0001). This is not surprising given
that Physiomesh/Securestrap contains an adhesion barrier
layer on both sides of the mesh material. These poligle-
caprone-25 (ie, Monocryl) absorbable barrier layers are
intended to minimize adhesions of the abdominal viscera
to the underlying mesh. However, the results of this study
suggest that the presence of this barrier layer on both
sides of the mesh may inhibit tissue ingrowth on the










Mesh contracture (%) 16.9  2.7 17.0  2.6 not applicable
Adhesion area (%) 1.2  0.7 6.0  3.5 not applicable
Adhesion tenacity 0.4  0.2 1.1  0.4 not applicable
T-peel strength
(N/cm)
1.4  0.1 0.9  0.1a 0.2  0.0b
Inflammation 2.1  0.1 3.3  0.2c not applicable
Type I collagen 3.3  0.2 3.5  0.2 not applicable
Type III collagen 0.7  0.2 0.5  0.2 not applicable
Fibrosis 0.0  0.0 1.2  0.3d not applicable
Hemorrhage 0.0  0.0 2.0  0.3c not applicable
Necrosis 0.0  0.0 0.0  0.0 not applicable
Angiogenesis 2.8  0.1 3.6  0.2e not applicable
a P  .0003 compared with Ventralight ST/SorbaFix.
b P  .0001 compared with Ventralight ST/SorbaFix.
c P  .0001 compared with Ventralight ST/SorbaFix.
d P  .0017 compared with Ventralight ST/SorbaFix.
e P  .0032 compared with Ventralight ST/SorbaFix.
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tissue ingrowth strength achieved with Physiomesh/
Securestrap compared with Ventralight ST/SorbaFix.
Histology
Ventralight ST/SorbaFix produced an inflammatory re-
sponse with a score of 2.1  0.1 compared with 3.3  0.2
for Physiomesh/Securestrap (Figure 4, Table 2). Inflam-
mation scores in this range indicated mild/slight inflam-
mation in Ventralight ST/SorbaFix specimens and moder-
ate inflammation in Physiomesh/Securestrap specimens.
Statistically, Physiomesh/Securestrap produced a signifi-
cantly greater inflammatory response than Ventralight ST/
SorbaFix (P  .0001). This inflammatory response was
primarily associated with the Monocryl layer of the Phys-
iomesh materials and, to a lesser degree, with the PP fibers
(Figures 4A and 4B). In Ventralight ST/SorbaFix speci-
mens, inflammation was associated with the PP fibers but
was also observed around and between the PGA fiber
bundles (Figures 4C and 4D).
Both groups exhibited similar amounts of type I and type
III collagen deposition, with scores of 3.3  0.2 and 0.7 
0.2, respectively, for Ventralight ST/SorbaFix and scores of
3.5  0.2 and 0.5  0.2, respectively, for Physiomesh/
Securestrap (Table 2). Type I collagen scores in the range
of 3.3 to 3.5 (on a scale of 0–4) indicated moderate to
marked amounts of type I collagen that were easily de-
tectable in the stained sections. Type III collagen scores in
the range of 0.5 to 0.7 (on a scale of 0–4) indicated
minimal/barely detectable amounts of type III collagen in
the stained sections. Statistically, there were no significant
differences between the two mesh-fixation combinations
for type I collagen (P  .3736) or type III collagen (P 
.3736).
Ventralight ST/SorbaFix produced fibrosis at the surface of
the mesh with a score of 0.0  0.0 compared with 1.2 
0.3 for Physiomesh/Securestrap (Table 2). Fibrosis scores
in this range indicated the absence of fibrosis in Ventra-
light ST/SorbaFix and minimal/barely detectable fibrosis
in Physiomesh/Securestrap. Statistically, Physiomesh/
Securestrap produced a significantly greater fibrotic re-
sponse compared with Ventralight ST/SorbaFix (P 
.0017). Fibroplasia was associated with active or ongoing
tissue ingrowth and granulation tissue formation in Phys-
iomesh/Securestrap. Active tissue ingrowth was already
Figure 4. Hematoxylin-eosin stain, original magnification 10. A, Inflammation score 3 in Physiomesh/Securestrap specimen. The
arrows indicate moderate inflammation. B, Inflammation score 4 in Physiomesh/Securestrap specimen. The arrows indicate marked
inflammation. C, Inflammation score 2 in Ventralight ST/SorbaFix specimen. The arrows indicate a mild foreign body response, and the
arrowheads indicate vacuolated macrophages. D, Inflammation score 3 in Ventralight ST/SorbaFix specimen. The arrows indicate a
moderate foreign body response, and the arrowhead indicates a minimal foreign body response. M  Monocryl, P  polypropylene.
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complete for Ventralight ST/SorbaFix, and more advanced
features of mature tissue integration were observed.
Similarly, Ventralight ST/SorbaFix exhibited no hemor-
rhage, with a score of 0.0  0.0, compared with mild/
slightly detectable hemorrhage, with a score of 2.0  0.3,
for Physiomesh/Securestrap (Table 2). Statistically, Physio-
mesh/Securestrap produced significantly greater hemorrhage
than Ventralight ST/SorbaFix (P  .0001). The microscopic
observations of hemorrhage for Physiomesh/Securestrap corre-
sponded with the macroscopic observations of widespread to
diffuse red discoloration at the time of explantation and were
associated with active and ongoing granulation tissue in-
growth, incomplete integration of the mesh, and incom-
plete tissue coverage of Physiomesh/Securestrap.
No evidence of necrosis was observed for either Ventra-
light ST/SorbaFix (0.0  0.0) or Physiomesh/Securestrap
(0.0 0.0) (Table 2). Statistically, there was no significant
difference in necrosis between the two mesh-fixation sys-
tems (P  .99).
Ventralight ST/SorbaFix exhibited angiogenesis with a
score of 2.8  0.1 compared with 3.6  0.2 for Physio-
mesh/Securestrap (Figure 5, Table 2). Angiogenesis
scores in this range indicated moderate angiogenesis in
Ventralight ST/SorbaFix specimens and moderate to
marked angiogenesis in Physiomesh/Securestrap speci-
mens. Specimens in both mesh groups displayed regularly
distributed vascular channels that supported fibrous con-
nective tissue ingrowth. Statistically, Physiomesh/Secur-
estrap produced significantly greater angiogenesis than
Ventralight ST/SorbaFix (P  .0032). Physiomesh/Secur-
estrap exhibited very dense arborizations of newly formed
vessels at the leading edge of the granulation tissue as it
progressed into the mesh (Figures 5A and 5B), whereas
Ventralight ST/SorbaFix showed an even distribution of
regularly spaced vascular channels throughout the mesh
(Figures 5C and 5D).
Finally, the SorbaFix and Securestrap fixation devices ex-
hibited a mild foreign body response associated specifi-
cally with structural features of the fixation devices, with
inflammation scores of 1.8  0.2 and 1.8  0.2, respec-
tively; fibrosis scores of 2.0  0.3 and 1.8  0.2, respec-
tively; and no evidence of erosion or degradation of the
fixation devices (ie, scores of 0.0  0.0 for both) after the
14-day implantation period (Figures 6A and 6B).
Figure 5. von Willebrand factor stain, original magnification 10. A, Angiogenesis score 3 in Physiomesh/Securestrap specimen. The
arrows indicate moderate density. B, Angiogenesis score 4 in Physiomesh/Securestrap specimen. The arrows indicate very high density.
C, Angiogenesis score 2 in Ventralight ST/SorbaFix specimen. Arrows indicate mild angiogenesis.D, Angiogenesis score 3 in Ventralight
ST/SorbaFix specimen. The arrows indicate moderate density. M  Monocryl.
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DISCUSSION
The objective of this study was to compare mesh contrac-
ture, adhesion characteristics (area covered by adhesions
and tenacity of adhesions), strength of tissue ingrowth,
and host tissue response associated with Ventralight ST/
SorbaFix compared with Physiomesh/Securestrap after
implantation for 14 days in a porcine model of LVHR.
The results of this study are comparable with those of an-
other study previously reported by our group, in which
Proceed, Sepramesh IP Composite, Ventrio, and Ventrio ST
materials were evaluated for mesh contracture, adhesion
characteristics, tissue ingrowth, and histologic response after
implantation for 28 days in a porcine model of LVHR.12 Aside
from the implantation time and the fact that SorbaFix was
used for all devices, all other methods were identical to those
in the current study. All meshes except Ventrio have absorb-
able barriers, providing relevant comparisons with the ab-
sorbable barrier meshes evaluated in this study. For instance,
the percent mesh contracture associated with Ventralight
ST/SorbaFix (17%) and Physiomesh/Securestrap (17%) in
this study are comparable with that of Ventrio (15%), slightly
greater than that of Sepramesh IP Composite (9%) and Ven-
trio ST (9%), and much lower than that of Proceed (27%)
reported in our previous study.12 In addition, the percentage
of mesh covered by adhesions (1.2%) and adhesion tenacity
(0.4) associated with Ventralight ST/SorbaFix in this study
are comparable with those of Ventrio (0.3% and 0.4, respec-
tively) and Sepramesh IP Composite (0.1% and 0.4, respec-
tively) in the previous study. However, the percentage of
mesh covered by adhesions (6.0%) and adhesion tenacity
(1.1) associated with Physiomesh/Securestrap in this study
more closely approximate those of Proceed (5% and 1.5,
respectively) and Ventrio ST (4% and 1.3, respectively) in the
previous study. Finally, the tissue ingrowth strength associ-
ated with Ventralight ST/SorbaFix (1.4 N/cm) in this study is
comparable with that of Ventrio (1.4 N/cm), Proceed (1.3
N/cm), and Ventrio ST (1.3 N/cm) in the previous study,
whereas the tissue ingrowth strength associated with Phys-
iomesh/Securestrap in this study (0.9 N/cm) is more compa-
rable with that of Sepramesh IP Composite (1.0 N/cm) in the
previous study.
It should be noted that the difference in implantation time
between this study (14 days) and our previous study (28
days) may impact these comparisons.12 A neoperitoneum
is expected to form within the first postoperative week, so
a 14-day implantation period provides adequate time for
evaluation of adhesion formation during/after this critical
period yet before full resorption of the barrier layer.7 A
14-day implantation period was also chosen for evalua-
tion of the initial phase of active barrier degradation and
resorption. Because most barrier layers require a resorp-
tion time of at least 30 days, it is possible that the inflam-
matory response to these materials is still fairly active
throughout the entire first postoperative month. At least
one preclinical model (intraperitoneal placement of mesh
in Wistar rats) has shown an increase in the formation
of adhesions between 7 and 30 days, perhaps because of
increased inflammation caused by the increased activity of
macrophages and fibroblasts as the barrier layer is actively
degraded and resorbed.20 Thus future studies should in-
vestigate implantation times on the order of 14, 30, and 90
days to better describe the progression of adhesions, tis-
sue ingrowth, and inflammation associated with these
materials over time. In addition, it is likely that the chem-
ical composition of the barrier layer also plays a role in the
associated inflammatory response and that this response
may vary with longer implantation times. Thus it is ex-
tremely important to evaluate multiple time points in fu-
ture studies to capture these differences. Trends observed
at a single, isolated time point such as 14 days may not be
representative of the overall trend that may occur over the
course of 30 and 90 days during and after the active
resorption of the barrier layer. In addition, future studies
should also incorporate other commonly used absorbable
barrier meshes for a more complete comparison of all
available materials. Of the 7 currently available absorbable
barrier hernia repair materials, only C-QUR and Parietex
Figure 6. Hematoxylin-eosin stain, original magnification 10. A,
Physiomesh/Securestrap. The single-headed arrows indicate Secur-
estrap, the arrowhead indicates chronic inflammatory response and
fibrosis along Securestrap, and the double-headed arrows indicate
Physiomesh. B, Ventralight ST/SorbaFix. The single-headed arrow
indicates SorbaFix fixation device, the arrowheads indicate chronic
inflammatory response and fibrosis along the SorbaFix fixation
device, and the double-headed arrows indicate Ventralight ST.
Ad  adipose tissue, M  abdominal muscle.
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Composite were not represented in this study or our
previous study.12 However, these materials have been
represented in several other preclinical5,13,14 and clinical11
studies that have measured parameters such as mesh con-
tracture, adhesion characteristics, tissue ingrowth, and his-
tologic response in a similar manner. It is difficult to make
direct comparisons among these studies and our results
because these studies often involved different hosts (ie,
rabbits or humans) or slightly different surgical techniques
(ie, abrasion of the bowel to induce adhesion formation).
In summary, Ventralight ST/SorbaFix and Physiomesh/
Securestrap exhibited similar mesh contracture, percent adhe-
sion coverage, adhesion tenacity, collagen deposition, and lev-
els of necrosis (P .05 in all cases) after a 14-day implantation
period in a porcine model of LVHR. However, Ventralight
ST/SorbaFix exhibited significantly less inflammation (P 
.0001), fibrosis (P  .0017), hemorrhage (P  .0001), and
angiogenesis (P  .0032) and significantly greater strength of
tissue ingrowth (P .0003) than Physiomesh/Securestrap after
the 14-day implantation period in this preclinical porcine study.
CONCLUSIONS
Ventralight ST/SorbaFix exhibited similar mesh contracture
and adhesion characteristics and more favorable strength of
tissue ingrowth and histologic response compared with
Physiomesh/Securestrap over the short-term 14-day implan-
tation period in this preclinical porcine study.
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